항생제 시장 : 약제 클래스별, 유형별, 스펙트럼별, 약제 유래, 투여 경로별, 용도별, 유통 채널별, 예측(2024-2032년)

The global antibiotics market is anticipated to record 3.3% CAGR from 2024 to 2032, owing to the escalating prevalence of infectious diseases worldwide.

As populations expand and urbanization accelerates, the risk of infectious outbreaks rises, necessitating heightened demand for effective antimicrobial treatments. According to the UN, the global population reached 8 billion in mid-November 2022 and will increase by nearly 2 billion people in the upcoming 30 years.

Additionally, the persistent challenge of antimicrobial resistance underscores the urgent need for innovative antibiotics. The increasing focus on healthcare infrastructure development, particularly in emerging economies, coupled with rising medical expenditure globally, amplifies the demand for antibiotics, driving the market forward.

The antibiotics market is classified based on drug class, type, spectrum, drug origin, route of administration, application, distribution channel, and region.

The penicillins segment is predicted to record strong demand by 2032, as they are known for their effectiveness against a wide range of bacterial infections, ranging from respiratory tract infections to skin infections. With the advancements in medical procedures and surgeries, the risk of postoperative infections has surged, necessitating antibiotics like penicillins for prophylactic and therapeutic purposes. The continuous development of novel formulations and the introduction of combination therapies bolster the demand for this drug class.

The generics type segment is expected to generate massive revenues by 2032, fueled by factors such as cost-effectiveness, ease of accessibility, and the expiration of patents for several branded antibiotics. Generic antibiotics offer a more affordable alternative to their branded counterparts, making them particularly attractive in both developed and developing markets. Additionally, stringent regulatory approvals and quality standards ensure the safety and efficacy of generic antibiotics, further driving their adoption globally.

Europe antibiotics market size will expand significantly through 2032 driven by factors such as a high prevalence of infectious diseases, well-established healthcare infrastructure, and strong government initiatives aimed at combating antimicrobial resistance. Countries across the region prioritize healthcare, leading to increased investments in R&D activities focused on novel antibiotic formulations and therapies. Furthermore, strategic collaborations between pharmaceutical companies and research institutions contribute to the region's prominence in the global antibiotics market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data collection
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of infectious disease
    • 3.2.1.2 Rising number of pharmaceutical and biotechnology companies
    • 3.2.1.3 Growing collaborations for antibiotics development
    • 3.2.1.4 Increasing focus on generic medications
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Antibiotic resistance
    • 3.2.2.2 Regulatory complexities
• 3.3 Growth potential analysis
• 3.4 Pipeline assessment
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2018-2032 ($ Million)

• 5.1 Key trends
• 5.2 Penicillins
• 5.3 Cephalosporins
• 5.4 Macrolides
• 5.5 Quinolones
• 5.6 Aminoglycosides
• 5.7 Tetracyclines
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Generics

Chapter 7 Market Estimates and Forecast, By Spectrum, 2018 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Broad-spectrum antibiotics
• 7.3 Narrow-spectrum antibiotics

Chapter 8 Market Estimates and Forecast, By Drug Origin, 2018 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Natural
• 8.3 Semisynthetic
• 8.4 Synthetic

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 Oral
• 9.3 Parenteral
• 9.4 Other routes of administration

Chapter 10 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Million)

• 10.1 Key trends
• 10.2 Respiratory infections
• 10.3 Urinary tract infections (UTIs)
• 10.4 Skin and soft tissue infections
• 10.5 Sexually transmitted infections (STIs)
• 10.6 Gastrointestinal infections
• 10.7 Other applications

Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

• 11.1 Key trends
• 11.2 Hospital pharmacies
• 11.3 Retail pharmacies
• 11.4 Online pharmacies

Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

• 12.1 Key trends, by region
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Rest of Europe
• 12.4 Asia Pacific
  • 12.4.1 Japan
  • 12.4.2 China
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 South Korea
  • 12.4.6 Rest of Asia Pacific
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Rest of Latin America
• 12.6 Middle East & Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 Rest of Middle East & Africa

Chapter 13 Company Profiles

• 13.1 Abbott Laboratories
• 13.2 AbbVie, Inc.
• 13.3 Allergan plc
• 13.4 Basilea Pharmaceutica Ltd.
• 13.5 Bayer AG
• 13.6 Bristol Myers Squibb
• 13.7 Cipla Inc.
• 13.8 Daiichi Sankyo Company Ltd.
• 13.9 Eli Lilly & Co.
• 13.10 GlaxoSmithKline plc.
• 13.11 Johnson & Johnson
• 13.12 Lupin Inc.
• 13.13 Melinta Therapeutics LLC
• 13.14 Merck & Co.
• 13.15 Novartis AG
• 13.16 Pfizer Inc.
• 13.17 Sandoz
• 13.18 Sanofi
• 13.19 Teva Pharmaceutical Industries Ltd.
• 13.20 Viatris Inc.